New Protocol for the Spectra Optia System
LAKEWOOD, Colo.—August 31, 2011— CaridianBCT, the leading global provider of technology, products and services in the blood banking, transfusion medicine and cell therapy industries announced today that the Spectra Optia System Mononuclear Cell (MNC) Collection protocol is now licensed by Health Canada and available for use in Canada.
The availability of the MNC protocol—in addition to the therapeutic plasma exchange (TPE) and red blood cell exchange (RBCX) protocols—on the Spectra Optia system brings the value of efficiency, purity and consistency to cell collections—benefitting patients, clinicians and laboratory processes. The newest protocol offers Canadian medical institutions high CD34+ collection efficiency, optimized procedure times and product purity. Operators are empowered with a reliable, flexible system that performs under a variety of operational and patient conditions.
"We remain steadfastly committed to enhancing our technology and introducing new protocols on the Spectra Optia system," said Tom Jordan, Executive Vice President, Global Commercial Operations. "The new MNC protocol advances cell collections through automation, performance reliability and product purity—allowing our customers to concentrate on what is important, their patients."
About Spectra Optia System:
Based on COBE® Spectra Apheresis System technology and the Trima Accel® Automated Blood Collection System platform, the Spectra Optia system is a transportable therapeutic apheresis system that uses centrifugation and optical detection technology (automated interface management or the AIM system). The MNC, TPE and RBCX protocols are also available in Europe, Africa, the Middle East, Australia and areas of Asia. The TPE protocol is available in the United States, however the MNC and RBCX protocols are not available for sale in the United States at this time.
The world's leading supplier of products and services in the blood banking, hospital and biotech industries, CaridianBCT serves customers with products that provide patients with the lifesaving gift of blood. Following the April 2011 Terumo Corporation acquisition, CaridianBCT and Terumo Transfusion will combine as the global leader in blood component technology. The combined entities remain dedicated to improving lives through products and services designed to meet the ever-expanding demand for safe, high-quality blood components. Headquartered in Lakewood, CO, the company has global operations in 32 countries and employs approximately 2,500 people. For more information, visit www.caridianbct.com.
Lisa Hayes, Vice President of Global Marketing and Corporate Communications
Phone: +1 303.231.4201